3 research outputs found
Six months follow up of a single intravitreal injection of ocriplasmin for symptomatic vitreomacular adhesion
Purpose: To evaluate the efficacy and the safety of the enzymatic vitreolysis with a single intravitreal injection of ocriplasmin 125
μg across a group of patients with symptomatic vitreomacular adhesion (sVMA) during 6 months follow up.
Design: A randomized, placebo-controlled, double-masked, 6-month follow up study.
Participants: A total of 28 patients (12 M / 16F) (19 receiving ocriplasmin; 9 receiving placebo), mean aged 71 years old,
diagnosed with sVMA, VMT, FTMH e ERM by optical coherence tomography.
Methods: A single intravitreal injection of ocriplasmin 125 μg or placebo. Primary endpoint was sVMA resolution or FTMH
closure. Secondary endpoint included the integrity of the external membrane and the inner and outer segments of the photoreceptor
interface using OCT. The evaluation was carried out at baseline and during 6 months after intravitreal injection of ocriplasmin or
placebo.
Results: After a 6 months follow-up period, the rate of VMA resolution was 42.1% in the Ocriplasmin group vs the 22% in the
placebo group. FTMH closure rate was 50% in the Ocriplasmin group vs 0% in the placebo group. The best results were optained
within 28 days from the treatment. No case of uveitis, endophthalmitis, retinal tears, retinal detachment or bleeding during followup
were reported. One patient reported floaters and transitional photopsias.
Conclusions: The study confirmed the efficacy and safety of Ocriplasmin injection for patients with VMT, including when
associated with full-thickness macular holes during six months follow up. Long term studies are certainly needed to confirm these
results
An eighteen-month follow-up study on the effects of intravitreal dexamethasone implant in diabetic macular edema refractory to anti-VEGF therapy
Abstract
AIM:
To evaluate the long-term efficacy and safety of dexamethasone implants in subjects affected by diabetic macular edema (DME) resistant to anti-vascular endothelial growth factor (VEGF) therapy.
METHODS:
Thirty-two DME patients were enrolled. A 700 microgram slow release Intravitreal Dexamethasone Implant (Ozurdex®) was placed in the vitreous cavity. All patients were followed for 18mo. Best-corrected visual acuity (BCVA) measured with Early Treatment Diabetic Retinopathy Study (ETDRS) and central macular thickness (CMT) exams were carried out at baseline (T0) and after 1 (T1), 3 (T3), 4 (T4), 6 (T6), 9 (T9), 12 (T12), 15 (T15), and 18mo (T18) post injection.
RESULTS:
Repeated measures ANOVA showed an effect of treatment on ETDRS (P<0.0001). Post hoc analyses revealed that ETDRS values were significantly increased at T1, T3, T4, T9, and T15 (P<0.001) as compared to baseline value (T0). At T6, T12, and T18, ETDRS values were still statistically higher than baseline (P<0.001 vs T0). However, at these time points, we observed a trend to return to baseline conditions. ANOVA also showed an effect of treatment (P<0.0001). CMT decreased significantly at T1, T3, T4, T9, and T15 (P<0.001). At T6 (P<0.01), T12 and T18 (P<0.001) CMT was also significantly lower than T0 although a trend to return to the baseline conditions was also observed.
CONCLUSION:
Our findings demonstrate that Intravitreal Dexamethasone Implant is a good option to improve BCVA and CMT in DME patients resistant to anti-VEGF therapy. Our data also show that the use of drugs administered directly into the vitreous allows achieving appropriate and long-lasting concentration at the site of disease without systemic side effects
Adverse events associated with intraocular injection of anti-VEGF(bevacizumab) in retinal vein ccclusion: a case report
Introduction: Antiangiogenic agents are often administered for treatment of Branch Retinal Vein
Occlusion (BRVO). Among them, Bevacizumab has noticeable antiangiogenic and antiedemigenic properties and
possesses great capacity to penetrate the retinal tissue, particularly in pathological circumstances characterized by
altered external or internal blood-retinal barrier.Bevacizumab has an optimal bio-efficacy based on inhibition of the
activity of Vascular Endothelial Growth Factor (VEGF). Nonetheless, despite its efficacy, here we describe the
adverse effects associated with intraocular injection of bevacizumab in a patient affected by retinal vein occlusion.
Case presentation: We present a case report of an 11-year old Caucasian malesubject affected by BRVO in his left
eye. The patient underwent an intra-vitreal (i.v.) injection of bevacizumab 100 (1.25 mg/0.05ml). After that, the
patient was monitored over time through a series of analyses including Ocular Coherence Tomography,
Fluorangiography, Bulbar Ultrasound, Angio MRI BCVA scores and Intra Ocular Pressure. Results: Immediately
after the i.v. injection, the patient experienced a strong and relentless pain radiating from the left ocular orbit, caused
by a serious and unexpected malignant glaucoma and phthisis bulbi. Furthermore, the patient did not show any sign
of improvement in visual function in the follow-up and at last required an ophthalmic prosthesisas a result of a subatrophic
and hypotonic eyeball. Conclusion: This case report suggests that i.v. injections of anti-VEGFs should be
considered wit